Back to search

Article

Serum metabolic signatures are associated with anti-drug antibody development in rheumatoid arthritis patients treated with adalimumab

2025-08-26

Abstract excerpt

<h4>Objectives</h4> Development of anti-drug antibodies (ADAs) is a barrier to long-term efficacy of biologic therapies in rheumatoid arthritis (RA), but no biomarkers exist to predict ADA formation. This study explored the potential of serum metabolomics to predict development of ADAs to adalimumab in patients with RA. <h4>Methods</h4> Serum from patients with RA (n=47), treatment naïve for tumour necrosis fact...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
629897b5-ce08-5241-b48d-48a08f0ff4fe
DOI
10.1101/2025.08.22.25334214
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Serum metabolic signatures are associated with anti-drug antibody development in rheumatoid arthritis patients treated with adalimumabDOI 10.1101/2025.08.22.25334214
Select a neighboring publication to make it the new centre.